

1. Identification

Product identifier	Bromodiphenhydramine Hydrochloride	
Other means of identification		
Catalog number	1077005	
Chemical name	Ethanamine, 2-[(4-bromophenyl)phenylmethoxy]-N,N-dimethyl-, hydrochloride	
Synonym(s)	Bromazine	
Recommended use	Specified quality tests and assay use only.	
Recommended restrictions	Not for use as a drug. Not for administration to humans or animals.	
Manufacturer/Importer/Supplier/Distributor information		
Company name	U. S. Pharmacopeia	
Address	12601 Twinbrook Parkway Rockville MD 20852-1790 US	
Telephone	RS Technical Services	301-816-8129
Website	www.usp.org	
E-mail	RSTECH@usp.org	
Emergency phone number	CHEMTREC within US & Canada	1-800-424-9300
	CHEMTREC outside US & Canada	+1 703-527-3887

2. Hazard(s) identification

Physical hazards	Not classified.	
Health hazards	Acute toxicity, oral	Category 4
	Specific target organ toxicity, single exposure	Category 3 narcotic effects
OSHA hazard(s)	Not classified.	
Label elements		



Signal word	Warning	
Hazard statement	Harmful if swallowed. May cause drowsiness or dizziness.	
Precautionary statement		
Prevention	Use only outdoors or in a well-ventilated area. Wash thoroughly after handling.	
Response	If swallowed: Call a poison center/doctor if you feel unwell. Rinse mouth. If inhaled: Remove person to fresh air and keep comfortable for breathing. Call a poison center/doctor if you feel unwell.	
Storage	Store in a well-ventilated place. Keep container tightly closed. Store locked up.	
Disposal	Dispose of contents/container in accordance with local/regional/national/international regulations.	
Hazard(s) not otherwise classified (HNOC)	Not classified.	

3. Composition/information on ingredients

Substance

Hazardous components

Chemical name	Common name and synonyms	CAS number	%
Bromodiphenhydramine Hydrochloride	Bromazine	1808-12-4	100

4. First-aid measures

Inhalation	Move to fresh air. Call a POISON CENTER or doctor/physician if you feel unwell.
Skin contact	Rinse skin with water/shower. Get medical attention if irritation develops and persists.
Eye contact	Rinse with water. Get medical attention if irritation develops and persists.
Ingestion	IF SWALLOWED: Call a POISON CENTER or doctor/physician if you feel unwell. Rinse mouth.
Most important symptoms/effects, acute and delayed	Narcotic effects.
Indication of immediate medical attention and special treatment needed	Treatment of antihistamine overdose should be symptomatic and supportive and may include the following: Administer activated charcoal as a slurry. For severe tachycardia, use beta blocking agents such as esmolol as a temporizing measure. For Torsades de Pointes: Administer magnesium, isoproterenol, and/or atrial overdrive pacing to stable patients. Hemodynamically unstable patients may require electrical cardioversion. Correct electrolyte abnormalities. For seizures, administer intravenous benzodiazepines. If seizures recur, consider phenobarbital. Monitor for hypotension, dysrhythmias, respiratory depression, and need for endotracheal intubation. Evaluate for hypoglycemia, electrolyte disturbances, and hypoxia. For hypotension: Infuse 10 to 20 mL/kg isotonic fluid. If hypotension persists, administer dopamine or norepinephrine. For agitation or dystonia, administer oral or intravenous benzodiazepines. Hemodialysis, hemoperfusion, peritoneal dialysis, and repeat-dose activated charcoal are not effective in removing antihistamines. (Meditext)
General information	Remove from exposure. Remove contaminated clothing. For treatment advice, seek guidance from an occupational health physician or other licensed health-care provider familiar with workplace chemical exposures. In the United States, the national poison control center phone number is 1-800-222-1222. If person is not breathing, give artificial respiration. If breathing is difficult, give oxygen if available. Persons developing serious hypersensitivity (anaphylactic) reactions must receive immediate medical attention.

5. Fire-fighting measures

Suitable extinguishing media	Use fire-extinguishing media appropriate for surrounding materials. Water. Foam. Dry chemical or CO ₂ .
Unsuitable extinguishing media	None known.
Specific hazards arising from the chemical	No unusual fire or explosion hazards noted.
Special protective equipment and precautions for firefighters	Wear suitable protective equipment.
Fire-fighting equipment/instructions	Use water spray to cool unopened containers. As with all fires, evacuate personnel to a safe area. Firefighters should use self-contained breathing equipment and protective clothing.
Specific methods	Use standard firefighting procedures and consider the hazards of other involved materials.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures	Keep unnecessary personnel away. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Avoid inhalation of dust from the spilled material. Wear appropriate personal protective equipment.
Methods and materials for containment and cleaning up	Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid the generation of dusts during clean-up. For waste disposal, see section 13 of the SDS. Clean surface thoroughly to remove residual contamination.

7. Handling and storage

Precautions for safe handling	As a general rule, when handling USP Reference Standards, avoid all contact and inhalation of dust, mists, and/or vapors associated with the material. Clean equipment and work surfaces with suitable detergent or solvent after use. After removing gloves, wash hands and other exposed skin thoroughly.
Conditions for safe storage, including any incompatibilities	Store in tight container as defined in the USP-NF. This material should be handled and stored per label instructions to ensure product integrity.

8. Exposure controls/personal protection

Biological limit values	No biological exposure limits noted for the ingredient(s).
Exposure guidelines	No exposure standards allocated.

Appropriate engineering controls	Airborne exposure should be controlled primarily by engineering controls such as general dilution ventilation, local exhaust ventilation, or process enclosure. Local exhaust ventilation is generally preferred to general exhaust because it can control the contaminant at its source, preventing dispersion into the work area. An industrial hygiene survey involving air monitoring may be used to determine the effectiveness of engineering controls. Effectiveness of engineering controls intended for use with highly potent materials should be assessed by use of nontoxic surrogate materials.
Individual protection measures, such as personal protective equipment	
Eye/face protection	Safety glasses with sideshields are recommended. Face shields or goggles may be required if splash potential exists or if corrosive materials are present. Approved eye protection (e.g., bearing the ANSI Z87 or CSA stamp) is preferred. Maintain eyewash facilities in the work area.
Skin protection	
Hand protection	Chemically compatible gloves. For handling solutions, ensure that the glove material is protective against the solvent being used. Use handling practices that minimize direct hand contact. Employees who are sensitive to natural rubber (latex) should use nitrile or other synthetic nonlatex gloves. Use of powdered latex gloves should be avoided due to the risk of latex allergy.
Other	For handling of laboratory scale quantities, a cloth lab coat is recommended. Where significant quantities are handled, work clothing may be necessary to prevent take-home contamination.
Respiratory protection	Where respirators are deemed necessary to reduce or control occupational exposures, use NIOSH-approved respiratory protection and have an effective respirator program in place (applicable U.S. regulation OSHA 29 CFR 1910.134).
Thermal hazards	Not available.
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.

9. Physical and chemical properties

Appearance	White to pale buff crystalline powder.
Physical state	Solid.
Form	Powder.
Odor	Faint odor.
Odor threshold	Not available.
pH	Not available.
Melting point/freezing point	291.2 - 293 °F (144 - 145 °C)
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not applicable.
Upper/lower flammability or explosive limits	
Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Explosive limit - lower (%)	Not available.
Explosive limit - upper (%)	Not available.
Vapor pressure	< 0.0000001 kPa at 25 °C
Vapor density	Not available.
Relative density	Not available.
Solubility in water	Very soluble.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Other information	
Chemical family	Ethanolamine derivative.
Molecular formula	C17H20BrNO.CIH

10. Stability and reactivity

Reactivity	No reactivity hazards known.
Chemical stability	Material is stable under normal conditions.
Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
Conditions to avoid	None known.
Incompatible materials	Oxidizing agents.
Hazardous decomposition products	Irritating and/or toxic fumes or gases. Emits toxic fumes under fire conditions. NOx SOx

11. Toxicological information

Information on likely routes of exposure

Ingestion	Harmful if swallowed.
Inhalation	Due to lack of data the classification is not possible.
Skin contact	Due to lack of data the classification is not possible.
Eye contact	Due to lack of data the classification is not possible.

Symptoms related to the physical, chemical, and toxicological characteristics For antihistamines: Nausea. Diarrhea. Headache. Drowsiness. Dizziness. Sore throat. Fever. Bleeding or bruising. Tiredness. Weakness. Thickening of mucus. Change in appetite. Change in weight. Dry mouth, nose, or throat. Blurred vision. Changes in vision. Confusion. Difficult or painful urination. Sweating. Sensitivity to sunlight. Ringing or buzzing in ears. Stomach pain. Skin rash. Chills. Clay-colored stools. Dark urine. Burning, prickly sensations. Tingling. Trouble sleeping. Clumsiness. Unsteadiness. Flushing. Trouble breathing. Fast heartbeat. Irregular heartbeat. Fixed or dilated pupils. Fainting. Hallucinations. Seizures.

Delayed and immediate effects of exposure For antihistamines: Coma. Death.

Cross sensitivity Persons sensitive to other antihistamines may be sensitive to this material also.

Medical conditions aggravated by exposure For antihistamines: Active alcoholism. Bronchial asthma. Hyperthyroidism. Heart disease. Hypertension. Urinary retention. Bladder neck obstruction. Prostate enlargement. Glaucoma. Peptic ulcer. Pyloric obstruction.

Acute toxicity Harmful if swallowed.

Product	Species	Test Results
Bromodiphenhydramine Hydrochloride (CAS 1808-12-4)		
<i>Oral</i>		
LD50	Mouse	366 mg/kg
	Rat	602 mg/kg

Skin corrosion/irritation Due to lack of data the classification is not possible.

Serious eye damage/eye irritation Due to lack of data the classification is not possible.

Respiratory sensitization Due to lack of data the classification is not possible.

Skin sensitization Due to lack of data the classification is not possible.

Germ cell mutagenicity Due to lack of data the classification is not possible. Data from germ cell mutagenicity tests were not found.

Carcinogenicity Due to lack of data the classification is not possible. This material is not considered to be a carcinogen by IARC, NTP, or OSHA.

Reproductive toxicity Due to lack of data the classification is not possible.

Specific target organ toxicity - single exposure Narcotic effects.

Specific target organ toxicity - repeated exposure Due to lack of data the classification is not possible.

Aspiration hazard Based on available data, the classification criteria are not met.

12. Ecological information

Ecotoxicity	No ecotoxicity data noted for the ingredient(s).
Persistence and degradability	No data is available on the degradability of this product.
Bioaccumulative potential	Not available.
Mobility in soil	Not available.
Other adverse effects	Not available.

13. Disposal considerations

Disposal instructions	Dispose in accordance with all applicable regulations. Under RCRA, it is the responsibility of the user of the product to determine, at the time of disposal, whether the product meets RCRA criteria for hazardous waste.
Local disposal regulations	Not available.
Hazardous waste code	Not available.
Waste from residues / unused products	Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).
Contaminated packaging	Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.

14. Transport information

DOT

Not regulated as a hazardous material by DOT.

IATA

Not regulated as a dangerous good.

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code No information available.

15. Regulatory information

US federal regulations CERCLA/SARA Hazardous Substances - Not applicable.
One or more components are not listed on TSCA.

Superfund Amendments and Reauthorization Act of 1986 (SARA)

Hazard categories Immediate Hazard - Yes
Delayed Hazard - No
Fire Hazard - No
Pressure Hazard - No
Reactivity Hazard - No

SARA 302 Extremely hazardous substance No

SARA 311/312 Hazardous chemical No

Other federal regulations

Safe Drinking Water Act (SDWA) Not regulated.

Food and Drug Administration (FDA) Not regulated.

US state regulations California Safe Drinking Water and Toxic Enforcement Act of 1986 (Proposition 65): This material is not known to contain any chemicals currently listed as carcinogens or reproductive toxins.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	Yes
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

16. Other information, including date of preparation or last revision

Issue date	04-06-2004
Revision date	08-07-2014
Version #	02
Further information	Not available.
Disclaimer	USP Reference Standards are sold for chemical test and assay purposes only, and NOT for human consumption. The information contained herein is applicable solely to the chemical substance when used as a USP Reference Standard and does not necessarily relate to any other use of the substance described, (i.e. at different concentrations, in drug dosage forms, or in bulk quantities). USP Reference Standards are intended for use by persons having technical skill and at their own discretion and risk. This information has been developed by USP staff from sources considered reliable but has not been independently verified by the USP. Therefore, the USP Convention cannot guarantee the accuracy of the information in these sources nor should the statements contained herein be considered an official expression. NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE is made with respect to the information contained herein.
Revision Information	This document has undergone significant changes and should be reviewed in its entirety.